Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Common Equity (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Common Equity for 12 consecutive years, with $64.4 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 428.22% to $64.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.4 million through Dec 2025, up 428.22% year-over-year, with the annual reading at $64.4 million for FY2025, 428.22% up from the prior year.
  • Common Equity hit $64.4 million in Q4 2025 for vTv Therapeutics, down from $70.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $70.5 million in Q3 2025 to a low of -$56.3 million in Q1 2021.
  • Historically, Common Equity has averaged -$2.5 million across 5 years, with a median of -$9.1 million in 2021.
  • Biggest five-year swings in Common Equity: tumbled 196.54% in 2023 and later soared 428.22% in 2025.
  • Year by year, Common Equity stood at -$9.7 million in 2021, then decreased by 10.27% to -$10.7 million in 2022, then crashed by 129.8% to -$24.7 million in 2023, then soared by 149.43% to $12.2 million in 2024, then skyrocketed by 428.22% to $64.4 million in 2025.
  • Business Quant data shows Common Equity for VTVT at $64.4 million in Q4 2025, $70.5 million in Q3 2025, and $2.4 million in Q2 2025.